BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27864344)

  • 41. Tumor Microenvironment-Mediated Construction and Deconstruction of Extracellular Drug-Delivery Depots.
    Hu Q; Sun W; Lu Y; Bomba HN; Ye Y; Jiang T; Isaacson AJ; Gu Z
    Nano Lett; 2016 Feb; 16(2):1118-26. PubMed ID: 26785163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response.
    Beyer K; Normann L; Sendler M; Käding A; Heidecke CD; Partecke LI; von Bernstorff W
    Pancreas; 2016 Mar; 45(3):401-8. PubMed ID: 26390425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nano-delivery of salvianolic acid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-β1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor.
    Chen Y; Hu M; Wang S; Wang Q; Lu H; Wang F; Wang L; Peng D; Chen W
    Int J Pharm; 2022 Jul; 623():121953. PubMed ID: 35753535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
    Zi X; Simoneau AR
    Cancer Res; 2005 Apr; 65(8):3479-86. PubMed ID: 15833884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer.
    Brancato V; Comunanza V; Imparato G; Corà D; Urciuolo F; Noghero A; Bussolino F; Netti PA
    Acta Biomater; 2017 Feb; 49():152-166. PubMed ID: 27916739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
    Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
    Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.
    Bremer E; van Dam GM; de Bruyn M; van Riezen M; Dijkstra M; Kamps G; Helfrich W; Haisma H
    Mol Ther; 2008 Dec; 16(12):1919-26. PubMed ID: 18813279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo.
    Li C; Yang Z; Du Y; Tang H; Chen J; Hu D; Fan Z
    Clin Cancer Res; 2014 Aug; 20(15):4001-13. PubMed ID: 25002124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
    Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
    J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anti-tumor effect of eukaryotic expressing plasmid containing soluble tumor necrotic factor-related apoptosis inducing ligand combined with human angiostatin Kringle (1 - 3) genes on human gastric cancer xenografts in nude mice].
    Sun W; Jiang Z; Xiang TX; Tao XH; Huang AL; Wang PL
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):841-5. PubMed ID: 19595126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor effects of recombinant human interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis.
    Li CG; Li ML; Shu XH; Liu YJ; Wu WS
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):981-6. PubMed ID: 20499068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
    Jiang X; Fitch S; Wang C; Wilson C; Li J; Grant GA; Yang F
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13857-13862. PubMed ID: 27849590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.
    Shivinsky A; Bronshtein T; Haber T; Machluf M
    Biomed Microdevices; 2015 Aug; 17(4):69. PubMed ID: 26044202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.